A Comprehensive Pharmaceutical Enterprise with Multi-Field

We are committed to the export of several API and intermediates, such as Azathioprine, Mercaptopurine, Ribavirin etc.
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. was founded in 1966, and now is a comprehensive modern pharmaceutical enterprise, specializing in the production of pharmaceutical capsules, injections, tablets, APIs, and pharmaceutical intermediates. The company took the lead in carrying out international certification in 1998, and many products have been approved by many countries and regions such as US FDA, EU EMEA, Australia TGA, UK MHRA, Mexico COFEPRIS and so on. As of May 2022, the company has built 9 GMP workshops, 5 chemical laboratories, 1 preparation laboratory, 1 new drug development department, and 1 pilot plant for new product development and production process technique transformation.
At present, the company can produce more than 70 varieties and nearly 100 specifications of drugs. Among them, Azathioprine, Mercaptopurine, and Ribavirin APIs have been certified by the US FDA and EU GMP several times. The sales market covers more than 20 countries and regions in Europe, America, India, South Africa, and Southeast Asia. At the same time, we also produce marine biomedicine 'glucosamine hydrochloride' series for the treatment and prevention of systemic osteoarthritis.
In the future, Cheng Yi Pharma will aim at the largest annual production in Asia of 2,000 tons of glucosamine hydrochloride API and 1000 tons of super fish oil (icosapent ethyl) projects, focusing on the Massive Health Industry. The 'Cheng Yi Pharma Marine Biomedicine Manufacturing Project' with an investment of 10 billion yuan has been basically completed. Among them, the trial production of ultra-high-purity fish oil EPA soft capsule was successful at the end of 2021. Next, we will launch a series of API and soft capsule products successively such as EPA, nervonic acid, etc. to realize the whole process, whole category, and industry chain layout from food to health products to medicine, striving to seize the heights of strategic commanding, empowering enterprise the new value, and accomplishing collectivizing and high-quality development of the company.
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance